AR053372A1 - Proteinas inmunologicas de lawsonia intracellularis - Google Patents

Proteinas inmunologicas de lawsonia intracellularis

Info

Publication number
AR053372A1
AR053372A1 ARP060101737A ARP060101737A AR053372A1 AR 053372 A1 AR053372 A1 AR 053372A1 AR P060101737 A ARP060101737 A AR P060101737A AR P060101737 A ARP060101737 A AR P060101737A AR 053372 A1 AR053372 A1 AR 053372A1
Authority
AR
Argentina
Prior art keywords
seq
sequence
polypeptide
sequence homology
amino acid
Prior art date
Application number
ARP060101737A
Other languages
English (en)
Inventor
Eric Martin Vaughn
Merrill Schaeffer
Yajie Liang
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Publication of AR053372A1 publication Critical patent/AR053372A1/es

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04Antibacterial agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911Bacteria
    • GPHYSICS
    • G01MEASURING; TESTING
    • G01NINVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2469/00Immunoassays for the detection of microorganisms
    • G01N2469/20Detection of antibodies in sample from host which are directed against antigens from microorganisms

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Analytical Chemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Microbiology (AREA)
  • Cell Biology (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

En la presente se proveen secuencias de ácidos nucleicos y aminoácidos utiles como la porcion inmunogénica de vacunas o composiciones inmunogénicas efectivas para aliviar la severidad de los síntomas clínicos asociados con la infeccion de Lawsonia intracellularis, o para conferir inmunidad protectora a un animal susceptible a esta infeccion. Las secuencias de aminoácidos preferidas se seleccionan del grupo que consiste en: 1) un polipéptido que comprende una secuencia seleccionada del grupo que consiste en SEQ ID N°: 1-455, SEQ ID N° 466, o el polipéptido codificado por SEQ ID N° 456, SEQ ID N° 457 o SEQ ID N° 466; 2) cualquier polipéptido que tiene al menos 85% de homología de secuencia, más preferiblemente al menos aproximadamente 90% de homología de secuencia, aun más preferiblemente al menos aproximadamente 95% de homología de secuencia, aun más preferiblemente al menos aproximadamente 97% de homología de secuencia, aun más preferiblemente al menos aproximadamente 98% de homología de secuencia, y aun más preferiblemente al menos aproximadamente 99% de homología de secuencia con el polipéptido de 1); 3) cualquier porcion inmunogénica de los polipéptidos de 1) y/o 2); 4) la porcion inmunogénica de 3), que comprende al menos 300, 290, 280, 270, 260, 250, 240, 230, 220, 210, 200, 190, 180, 170, 160, 150, 140, 130, 120, 110, 100, 90, 80, 70, 60, 50, 45, 40, 35, 30, 25, 20, 18, 15, 13, 10, o más preferiblemente 9 aminoácidos contiguos incluidos en las secuencias de SEQ ID N° 1-455, SEQ ID N° 456, o la secuencia de aminoácidos codificada por SEQ ID N° 457 o SEQ ID N° 466; y/o 5) un polipéptido codificado por un ADN que codifica un péptido que comprende la SEQ ID N° 1-455 o SEQ ID N° 466. Por consiguiente, las secuencias de ácidos nucleicos que codifican estas proteínas, o las proteínas mismas, se incluyen en composiciones de vacunas, en combinacion con vehículos aceptables para el uso veterinario, y se las administra a un animal que las necesita.
ARP060101737A 2005-04-28 2006-04-28 Proteinas inmunologicas de lawsonia intracellularis AR053372A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US67580605P 2005-04-28 2005-04-28
US11/414,764 US20080279893A1 (en) 2005-04-28 2006-04-28 Lawsonia intracellularis immunological proteins

Publications (1)

Publication Number Publication Date
AR053372A1 true AR053372A1 (es) 2007-05-02

Family

ID=38006679

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP060101737A AR053372A1 (es) 2005-04-28 2006-04-28 Proteinas inmunologicas de lawsonia intracellularis

Country Status (6)

Country Link
US (1) US20080279893A1 (es)
EP (1) EP1877580A4 (es)
JP (1) JP2009509496A (es)
AR (1) AR053372A1 (es)
TW (1) TW200716166A (es)
WO (1) WO2006116763A2 (es)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8834891B2 (en) 2005-03-14 2014-09-16 Boehringer Ingelheim Vetmedica, Inc. Immunogenic compositions comprising Lawsonia intracellularis
US8398994B2 (en) 2005-07-15 2013-03-19 Boehringer Ingelheim Vetmedica, Inc. Lawsonia vaccine and methods of use thereof
US8470336B2 (en) 2006-05-25 2013-06-25 Boehringer Ingelheim Vetmedica, Inc. Vaccination of young animals against Lawsonia intracellularis infections
US20080241190A1 (en) * 2006-11-13 2008-10-02 Boehringer Ingelheim Vetmedica, Inc. Vaccination of horses against lawsonia intracellularis
WO2008073464A2 (en) 2006-12-11 2008-06-19 Boehringer Ingelheim Vetmedica, Inc. Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
WO2009037262A2 (en) 2007-09-17 2009-03-26 Boehringer Ingelheim Vetmedica, Inc. Method of preventing early lawsonia intracellularis infections
JP2012506858A (ja) * 2008-10-23 2012-03-22 インターベット インターナショナル ベー. フェー. Lawsoniaintracellularisワクチン
US20140017268A1 (en) * 2012-06-05 2014-01-16 Regents Of The University Of Minnesota Composition and Methods for Detecting or Preventing Lawsonia intracellularis Infections
CL2017002196A1 (es) * 2017-08-30 2017-11-17 Univ De Concepción Vacuna recombinante contra enteropatía proliferativa en animales.
CN112940089B (zh) * 2021-01-27 2022-09-09 湖南康保特生物科技有限公司 胞内劳森菌flgE重组蛋白及胞内劳森菌抗体检测试剂盒

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0871735B1 (en) * 1995-11-30 2006-06-07 Agriculture Victoria Services Pty Ltd Therapeutic compositions for the treatment of Lawsonia intracellularis infections
EP1570045A4 (en) * 2002-10-04 2007-09-05 Univ Minnesota NUCLEIC ACID AND POLYPEPTIDE SEQUENCES FROM LAWSONIA INTRACELLULARIS AND METHOD OF USE

Also Published As

Publication number Publication date
WO2006116763A3 (en) 2007-11-08
JP2009509496A (ja) 2009-03-12
EP1877580A2 (en) 2008-01-16
EP1877580A4 (en) 2008-07-30
WO2006116763A2 (en) 2006-11-02
TW200716166A (en) 2007-05-01
US20080279893A1 (en) 2008-11-13

Similar Documents

Publication Publication Date Title
AR053372A1 (es) Proteinas inmunologicas de lawsonia intracellularis
HRP20191594T1 (hr) Poticanje imunosnog odgovora
AR107020A2 (es) Vacuna de pcsk9 (proteína convertasa subtilisina-kexina tipo 9)
AR064642A1 (es) Polinucleotido vector que lo comprende celula recombinante que comprende el vector polipeptido , anticuerpo , composicion que comprende el polinucleotido , vector , celula recombinante polipeptido o anticuerpo , uso de la composicion y metodo para preparar la composicion misma y preparar una composi
HRP20231496T1 (hr) Cistein proteaza
PE20140986A1 (es) Proteinas de fusion y vacunas de combinacion que comprenden proteina e y pilina a de haemophilus influenzae
RU2015142981A (ru) Белки rsv в предшествующей слиянию конформации и их применение
HRP20140109T1 (hr) Novi imunoadjuvantni spojevi na bazi flagelina i njihova upotreba
SI2280721T1 (en) IMUNOTHERAPY BASED ON INDOLEAMINE 2,3-DIOXYGENESIS
ATE470673T1 (de) Impfstoffe mit lawsoniaintrazellularis- untereinheit
AR083839A1 (es) Virus del sindrome reproductivo y respiratorio porcino (prrs) de los estados unidos y sus usos
JP2020509770A5 (es)
AR094725A1 (es) Parvovirus 5a porcino, métodos de uso y vacuna
WO2009024327A3 (en) New proteins for use in human and animal staphylococcus infections
PE20061441A1 (es) Genes y proteinas novedosos de brachyspira hyodysenteriae y uso de los mismos para diagnostico y terapia
NZ598605A (en) Vaccine against african horse sickness virus
JP2012516140A5 (es)
AR071696A1 (es) Vacuna contra leishmania usando un inmunogeno salival de la mosca de la arena. metodos.
AR123187A1 (es) Vacuna de múltiples epítopos para el tratamiento de la enfermedad de alzheimer
WO2006113782A3 (en) Lawsonia protein useful as a component in subunit vaccine and methods of making and using thereof
ATE450545T1 (de) Impfstoff mit lawsonia intracellularis- untereinheit
RU2009115688A (ru) Иммуногенные гибридные полипептиды против ожирения и композиция вакцин против ожирения, содержащая эти полипептиды
ATE435660T1 (de) Immunogenes polypeptid bestehend aus optimierten kryptischen peptiden aus tumorantigenen und seine verwendungen
TW200801034A (en) Novel sea lice vaccine
EA201501001A1 (ru) Вакцина для профилактики и лечения ротавирусной инфекции, содержащая гибридный белок в качестве активного агента (варианты)

Legal Events

Date Code Title Description
FB Suspension of granting procedure